Latest Breaking News On - Edwards therapeutics - Page 1 : comparemela.com

The novel agent most benefited those with low systolic BP, often excluded from major HF trials, but didn t help outcomes when baseline pressures were higher, post hoc analysis of GALACTIC-HF suggests.

United kingdomVifor pharmaMarco metraBristol myers squibbDrug administrationUniversity of bresciaBoehringer ingelheimUniversity of glasgowHeart failure associationEuropean societyEuropean heartAbbott vascularEdwards therapeuticsFailure associationHeart failureCongestive heart failure